National Institute on Drug Abuse - Intramural Research Program
Featured Paper of the Month – January 2025
Published in Nature Communications by Zhewei Zhang, Yuji Takahashi and Geoffrey Schoenbaum et al. of the NIDA IRP Behavioral Neurophysiology Neuroscience Section.
We studied rats with hippocampus damage as they played a smell-based game. The game involved four contexts with different reward structures changing over time.
Featured Paper of the Month – December 2024
Published in Nature Communications Biology by András H Lékó, Adriana Gregory-Flores and Lorenzo Leggio et al. of the NIDA IRP Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section.
In this study. we investigated whether the deletion of the GHSR gene (GHSR-KO) in rats can prevent or attenuate weight gain caused by a high-fat diet.
Featured Paper of the Month – November 2024
Published in Neuropsychopharmacology by Flavia Barbano and Marisela Morales, et al. of the NIDA IRP Neuronal Networks Section.
Our study shows that activating a parallel VTA-originating glutamatergic pathway targeting the NAc shell can suppress psychostimulant-seeking behavior.
Featured Paper of the Month – October 2024
Published in Neuropharmacology by Hui Shen, Zilu Ma and Yihong Yang, et al. of the NIDA IRP Magnetic Resonance Imaging and Spectroscopy Section.
In this study, we used the delay-discounting task (DDT) to identify rats with different levels of impulsivity.
Featured Paper of the Month – September 2024
Published in PNAS with contributions from Salvatore Giorgi and Brenda Curtis of the NIDA IRP Technology and Translational Research Unit.
This study shows how race moderates the relationship between language and depression, with I-usage predicting depression in White individuals but not in Black individuals.
Featured Paper of the Month – August 2024
Published in Nature Communications by Flavia Barbano and Marisela Morales, et al. of the NIDA IRP Neuronal Networks Section.
Defensive behaviors are critical actions evolutionary selected to improve survival. Barbano et al., discovered an unanticipated neuronal pathway that is activated during threatening environmental conditions.
Featured Paper of the Month – July 2024
Published in Jama Network Open by Kirsten Smith and David Epstein, et al. of the NIDA IRP Real-world Assessment, Prediction, and Treatment Unit.
This was the first-ever study to use real-time, app-based monitoring of patterns and consequences of kratom use, in 357 people who used kratom daily or almost daily.
Featured Paper of the Month – June 2024
Published in Molecular Psychiatry by Marjorie Levinstein and Michael Michaelides, et al. of the NIDA IRP Biobehavioral Imaging and Molecular Neuropsychopharmacology Section.
In this article we performed an in depth in vivo, in vitro, and in silico analysis of (R,S)-methadone and its enantiomers. (S)-methadone is currently in phase III trials as an antidepressant and is frequently referred to as an N-methyl-D-aspartate receptor (NMDAR) antagonist, like ketamine. Here we show that (S)-methadone, like (R)-methadone and (R,S)-methadone is an agonist at the mu opioid receptor (MOR) and does not bind to NMDARs at physiologically relevant concentrations.
Featured Paper of the Month – May 2024
Xylazine, an increasingly abused drug mixed with fentanyl, leads to devastating respiratory issues during fentanyl-xylazine overdose. Despite naloxone being the primary treatment, it falls short in fully reversing the hypoxic effects of the drug mixture. Our study suggests that supplementing naloxone with atipamezole, a xylazine antagonist, provides a more effective and thorough solution for addressing brain hypoxia caused by fentanyl-xylazine mixture.
Featured Paper of the Month – April 2024
Published in Frontiers in Public Health by Salvatore Giorgi and Brenda Curtis, et al. of the NIDA IRP Technology and Translational Research Unit.
In this work, we apply a computational linguistic framework to measure dehumanization to 3 million news articles. We show that popular media in the U.S. has dehumanized people who used substances to varying degrees. Substances such as heroin have been strongly dehumanized for decades, while marijuana use is becoming less dehumanized over time, aligning with increased public support for legalization.
